Sichenzia Ross Ference LLP Represents Genetic Technologies Limited in $1.8 Million Registered Direct Offering
Press Release – New York, NY – April 3, 2020 – Sichenzia Ross Ference LLP today announced that it represented Genetic Technologies Limited (NASDAQ: GENE), a leader in the development of genetic risk assessment tests, in a registered direct offering of 1,028,574 American Depositary Shares (ADSs), each representing six hundred of the Company’s ordinary shares, at a purchase price of $1.75 per ADS.
The ADSs had been registered on a registration statement on Form F-3 (File No. 333-237152) declared effective by the Securities and Exchange Commission on March 23, 2020.
The Sichenzia Ross Ference LLP team was led by partners Darrin Ocasio and Avital Perlman, counsel Jeffrey Cahlon, and associate Yian Pan.
- Sichenzia Ross Ference LLP Represents Lexaria Bioscience Corp. in Close of $11 Million Underwritten Public Offering and NASDAQ Uplisting - January 15, 2021
- Partner Andrew M.J. Bernstein to Present CLE on “Preparing Your Client to Testify Before a Grand Jury” for Lawline - January 11, 2021
- Sichenzia Ross Ference LLP Represents KULR Technology Group, Inc. in $8.0 Million Registered Direct Offering - January 4, 2021